Related Experiment Video
Updated: Jul 19, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Paclitacxel and carboplatin in advanced non-small-cell lung cancer
1Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangshou Road, Nanjing 210029, Jiangsu Province, China. kaixin448@hotmail.com
Abstract:
To evaluate the efficacy and toxicity of the combination of paclitacxel and carboplatin on advanced non-small-cell lung cancer (NSCLC). Forty-eight patients with locally advanced (stage IIIb) or metastatic (stage IV) NSCLC were enrolled into the study. The patients received paclitacxel 55-60 mg/m(2) on day 1, 8, 15, carboplatin at an AUC of 5 on day 1, administreted in 28-day cycle. An objective response was obtained in 37.5% of patients (two complete and 16 partial responses). Significant difference existed between the naive patients and pretreated patients (46.4% vs. 25.0%, P<0.05). The main toxicities were bone marrow suppression, nausea/vomiting and alopecia. The combination of paclitacxel and carboplatin is an effective, well-tolerated scheme in the treatment of advanced NSCLC. The efficacy is higher in the naive group than in the pretreated group.
Related Concept Videos
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

